Peginterferon alfa-2b - Enzon/Merck & Co.
Alternative Names: Cylatron; Interferon-alpha-2b macrogol; Intron A Peg; PEG interferon-alpha-2b; PEG-Intron; PEG-Intron A; PEG-Intron-A; Pegatron; PEGIFN; PegIntron; Pegintron; Pegtron; Pegylated IFN alfa-2b; Pegylated IFN-alpha 2b; Pegylated interferon-alpha-2b; pIFN - alpha 2b; Polyethylene glycol interferon-alpha-2b; SCH 54031; Sylatron; ViraferonPegLatest Information Update: 06 May 2024
At a glance
- Originator Enzon Pharmaceuticals
- Developer Enzon Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; Hoosier Cancer Research Network; Merck & Co; Novartis; Schering-Plough; VU University Medical Center; Wistar Institute
- Class Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Interferons; Polyethylene glycols; Skin disorder therapies
- Mechanism of Action Interferon alpha replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B; Hepatitis C; Malignant melanoma
- Phase II Cholangiocarcinoma; HIV infections
- Discontinued Chronic myeloid leukaemia; Multiple sclerosis; Polycythaemia vera; Solid tumours
Most Recent Events
- 03 Mar 2024 Pharmacodynamics data from the phase I BEAT-2 trial in HIV-1 infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)
- 28 May 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (SC, Injection)
- 19 Feb 2023 Efficacy data from the phase I BEAT-2 trial in HIV-1 infections presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)